Clinical Research Directory
Browse clinical research sites, groups, and studies.
Quantify the Value of Transmural Inflammation in the Treatment of Crohn's Disease With Ustekinumab:an Analysis Based on Imaging Science
Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
Summary
Crohn's disease(CD),a type of inflammatory bowel disease(IBD), is a chronic intestinal recurrent inflammatory disease involving the entire digestive tract. And Ustekinumab, a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23, is a newly targeted drug approved for the treatment of Crohn's disease in recent years.Based on the high-throughput imaging characteristic analysis technique, this study quantitatively analyzed the transmural inflammation of Crohn's disease, and discussed its prognostic value in the treatment of Ustekinumab, and further analyzed the increment of its relative clinical index.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
150
Start Date
2022-07-01
Completion Date
2023-01-31
Last Updated
2026-04-29
Healthy Volunteers
No
Locations (1)
the Sixth Affiliated Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China